{"id":50800,"date":"2025-07-21T02:38:47","date_gmt":"2025-07-21T06:38:47","guid":{"rendered":"https:\/\/thestockmarketwatch.com\/stock-market-news\/corporate-updates-stellantis-faces-h1-loss-astrazenecas-lung-cancer-drug-shows-promise-roches-copd-drug-mixed\/50800\/"},"modified":"2025-07-21T02:38:47","modified_gmt":"2025-07-21T06:38:47","slug":"corporate-updates-stellantis-faces-h1-loss-astrazenecas-lung-cancer-drug-shows-promise-roches-copd-drug-mixed","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/corporate-updates-stellantis-faces-h1-loss-astrazenecas-lung-cancer-drug-shows-promise-roches-copd-drug-mixed\/50800\/","title":{"rendered":"Corporate Updates: Stellantis Faces H1 Loss, AstraZeneca&#8217;s Lung Cancer Drug Shows Promise, Roche&#8217;s COPD Drug Mixed"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Stellantis (<a href=\"\/stock\/STLA\">STLA<\/a>)<\/strong> reported preliminary <strong>Q2 shipments down 6% year-over-year to 1.4 million units<\/strong>, with North American shipments plummeting <strong>25%<\/strong>, contributing to an estimated <strong>H1 net loss of \u20ac2.3 billion<\/strong>.<\/li>\n<li><strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> announced that its drug <strong>Tagrisso<\/strong>, combined with chemotherapy, demonstrated <strong>statistically significant and clinically meaningful improvement in overall survival<\/strong> for patients with <strong>EGFR-mutated advanced lung cancer<\/strong> in the FLAURA2 trial.<\/li>\n<li><strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> faced a setback as its experimental drug, astegolimab, for <strong>Chronic Obstructive Pulmonary Disease (COPD)<\/strong> yielded <strong>mixed results<\/strong> in late-stage trials.<\/li>\n<\/ul>\n<p><strong>Stellantis (<a href=\"\/stock\/STLA\">STLA<\/a>)<\/strong> has released preliminary financial figures for the first half of 2025, revealing a challenging period. The automotive giant reported an estimated <strong>net loss of \u20ac2.3 billion<\/strong> for H1, alongside <strong>negative industrial free cash flows of \u20ac3.0 billion<\/strong> and an adjusted operating income estimated at <strong>\u20ac0.5 billion<\/strong>.<\/p>\n<p>In the second quarter, Stellantis&#39;s global shipments declined <strong>6% year-over-year to 1.4 million units<\/strong>. North America experienced a significant drop, with shipments down <strong>25% year-over-year to 322,000 units<\/strong>. Despite the declines in shipments, Q2 net revenues are estimated at <strong>\u20ac74.3 billion<\/strong>.<\/p>\n<p>On the pharmaceutical front, <strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> delivered positive news regarding its lung cancer treatment. The company announced that its drug <strong>Tagrisso<\/strong> (osimertinib), when combined with chemotherapy, showed a <strong>statistically significant and clinically meaningful improvement in overall survival<\/strong> for patients suffering from <strong>EGFR-mutated advanced lung cancer<\/strong>. These promising results stem from the FLAURA2 Phase III trial and indicate a <strong>favorable trend toward overall survival improvement at two years of follow-up<\/strong>, alongside a manageable safety profile.<\/p>\n<p>Conversely, <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> encountered mixed outcomes for its experimental drug astegolimab, intended for the treatment of a deadly lung condition, specifically <strong>Chronic Obstructive Pulmonary Disease (COPD)<\/strong>. While one Phase 2b study showed a <strong>15.4% reduction in exacerbations<\/strong> (worsening of the condition), the drug ultimately <strong>failed to meet its primary goal in another trial<\/strong>. This represents a setback for Roche as it continues efforts to accelerate the development of new treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Stellantis (STLA) reported preliminary Q2 shipments down 6% year-over-year to 1.4 million units, with North American shipments plummeting [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[6258,1807,6259,5199,5625,5775,6253,6254,6255,6256,6257],"class_list":["post-50800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-rhhby-stock-rhhby","tag-earnings","tag-copd","tag-automotive","tag-stellantis","tag-pharmaceuticals","tag-astrazeneca","tag-roche","tag-clinical-trials","tag-stla-stock-stla","tag-azn-stock-azn"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/50800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=50800"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/50800\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=50800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=50800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=50800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}